MREO · Mereo BioPharma Group plc · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| GBP | — | — | — | — | -936K | 17.91M |
| $495K | $465K | $438K | $395K | $0 | — | |
| -$176K | $104K | $0 | $2.13M | $840K | — | |
| — | $300K | $0 | -$10K | $1.09M | — | |
| -$31.74M | -$33.85M | -$44.62M | -$25.26M | -$52.88M | — | |
| USD/shares | -$0.03 | -$0.05 | -$0.06 | -$0.04 | -$0.07 | — |
| USD/shares | -$0.03 | -$0.05 | -$0.06 | -$0.04 | -$0.07 | — |
| shares | — | 797.12M | 739.62M | 659.45M | 603.2M | — |
| shares | — | 797.12M | 739.62M | 659.45M | 603.2M | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2019: $1.31M in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 277 similar-size Biotechnology companies (of 536 listed).